Cardio Diagnostics Holdings Inc. · NASDAQ:CDIO
Cardio Diagnostics — Corporate Update (May 2023)
40 slides from Cardio Diagnostics's corporate update, May 16, 2023
Slide 1: Company Update May 2023
COMPANY UPDATE MAY 2023 Revolutionizing Cardiovascular Medicine With Epigenetics and AI
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements and information included in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this presentation, the words or phrases “will”, "will likely result," "expected to," "
Slide 3: Key Investment Highlights
Key Investment Highlights NASDAQ listed: CDIO - market cap $19 million as of 5/15/2023 Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized and precise Launche
Slide 4: Mission to Revolutionize Cardiovascular Medicine with Epigenetics and AI
Cardio Diagnostics’ Mission is to Revolutionize Cardiovascular Medicine with Epigenetics and AI Our Vision: Precision Cardiovascular Medicine, driven by epigenetics and artificial intelligence, will transform the delivery of targeted interventions, enhance patient outcomes, and reduce costs, ultimat
Slide 5: Pioneering a New Era in Precision Cardiovascular Medicine
Cardio Diagnostics is Pioneering a New Era in Precision Cardiovascular Medicine Driven by Innovation, Diversification, Scale and Experience INNOVATION DIVERSIFICATION Only precision molecular diagnostics technology for Multiple launched and in development synergistic cardiovascular disease at the in
Slide 6: Pioneering a New Era: Scale and Experience
Cardio Diagnostics is Pioneering a New Era in Precision Cardiovascular Medicine Driven by Innovation, Diversification, Scale and Experience SCALE EXPERIENCE Highly scalable and efficient testing and reporting Has profound understanding of clinical needs, process. challenges and opportunities. Favora
Slide 7: Cardiovascular Disease is the Leading Cause of Death Globally
Cardiovascular Disease is the Leading Cause of Death Globally Despite Being Largely Preventable Cardiovascular disease (CVD) is the leading cause of death globally, accounting for nearly 19 million deaths per year, or about 32% of all global deaths ⁽¹⁾ Globally, cardiovascular disease is expected to
Slide 8: Cardiovascular Disease is a Burden for All Major Stakeholders
Cardiovascular Disease is a Burden for All Major Stakeholders Employers Providers and Provider Payers Organizations Employers can face increased healthcare Heart disease accounts for approximately Heart disease is responsible for a costs due to heart disease, as employees 25% of emergency room visit
Slide 9: Four Strategic Steps to Realize Our Vision
Four Strategic Steps to Realize Our Vision Build comprehensive evidence that matter to key healthcare stakeholders Rigorous clinical and analytic validation of biomarkers and Artificial Intelligence models Health economic studies to demonstrate substantial savings and ROI Establish a robust product
Slide 10: Clinicians' Current Approach to Assessing Risk and Detecting CVD
Clinicians’ Current Approach to Assessing Risk for and Detecting Cardiovascular Disease Currently, risk for CVD is assessed using two Currently, CVD is detected using several tests: common lipid-based clinical tests: FRAMINGHAM RISK SCORE Exercise ECG Cardiac Catheterization (FRS) Measures the elect
Slide 11: Two Types of DNA Biomarkers Power Our Approach
Two Types of DNA Biomarkers Power Our Approach GENETICS (SINGLE NUCLEOTIDE POLYMORPHISMS) Inherited from parents <20% of risk for cardiovascular disease is driven by genetics⁽¹⁾ Does not change over time (i.e., not dynamic) EPIGENETICS (DNA METHYLATION) Influenced by lifestyle & environment Larger d
Slide 12: Our AI-Driven Integrated Epigenetic-Genetic Engine
Our AI-Driven Integrated Epigenetic-Genetic Engine™ Proprietary Engine designed and built over the past decade BIG DATA HIGH-PERFORMANCE DOMAIN EXPERTISE PRODUCT COMPUTING, ML/AI AND DOMAIN EXPERTISE Billions of genetic, Non-linear data Lab translation of Lab profiling using epigenetic & mining assa
Slide 13: Cardio Diagnostics' Suite of Solutions
Cardio Diagnostics’ Suite of Solutions Epi+Gen CHD™ PrecisionCHD™ Only epigenetics-based test in the world for coronary heart disease Only epigenetics-based test in the world for coronary heart risk assessment disease detection It is a more sensitive and non-invasive alternative to the Framingham It
Slide 14: Differentiated Solutions Address Needs of Major Healthcare Stakeholders
Our Differentiated Solutions Address the Needs of Major Healthcare Stakeholders Reduce absenteeism Improve well-being and improve and quality of life productivity among Receive timely and employees better care Patients Employers Reduce healthcare costs by avoiding costly disease management Better cl
Slide 15: Clear, Key Differentiations for Coronary Heart Disease
Clear, Key Differentiations for Coronary Heart Disease Hospitals & GROWTH STRATEGIES Clinics SENSITIVE EPIGENETICS BASED TEST CORONARY HEART DISEASE SPECIFIC PHYSICIAN ORDERED AND/OR INTERPRETED AT-HOME TESTING AVAILABLE MULTIPLE DNA BIOMARKERS-BASED TEST MONITOR TREATMENT RESPONSE ⁽¹⁾ ⁽²⁾ ⁽¹⁾ Compa
Slide 16: A $185B US Total Addressable Market
Epi+Gen CHD™ and PrecisionCHD™: A $185B US Total Addressable Market⁽¹⁾ We expect to accelerate the Epi+Gen CHD™ is recommended We intend to accelerate the adoption of Epi+Gen CHD™ and for: adoption of both tests by: PrecisionCHD™ across several Adults ages 35-75 channels including: Have not been dia
Slide 17: The Engine Can be Leveraged Repeatedly
The Integrated Genetic-Epigenetic Engine™ Can be Leveraged Repeatedly Assumes one patient could be tested with multiple tests⁽¹⁾ *Represents expected launch date LAUNCHED LAUNCHED 2023/2024* 2023/2024* 2024/2025* EPI+GEN CHD CHD DETECTION CHF RISK STROKE RISK DIABETES RISK 146M adults 157M adults 15
Slide 18: A Scalable Testing & Reporting Process
A Scalable Testing & Reporting Process to Fulfill Increasing Demand REMOTE Telemedicine provider At-home lancet sample orders test for patient collection kit shipped to patient 1a 2a 3 4 5 6 7 Collect blood Ship blood Lab processing Process data Share patient 1b 2b sample sample overnight of blood a
Slide 19: FDA Regulatory Pathway Enables More Labs to Process Tests
FDA Regulatory Pathway Enables More Labs to Process Tests START COMPLETED ONGOING 70-80 DAYS 5 DAYS 1 2 3 4 Determine appropriate FDA Assemble FDA pre-submission Submit pre-submission to FDA Receive FDA comments & pathway based on input from to receive feedback from FDA for detailed comments on meet
Slide 20: Pursuing A New Standard of Care for Cardiovascular Medicine
Pursuing A New Standard of Care for Cardiovascular Medicine KOLs⁽¹⁾ & EVIDENCE BUILDING ENGAGE PAYORS CODE, COVERAGE REIMBURSEMENT (e.g. research studies, & PAYMENT CONSULTANT health economics) ⁽¹⁾ KOLs: Key Opinion Leaders © Cardio Diagnostics Holdings Inc., May 2023. All rights reserved.
Slide 21: Short-Term & Long-Term Strategic Initiatives
Robust Short-Term & Long-Term Strategic Initiatives GROWTH STRATEGIES INCREASE REVENUE MANAGE RISKS REDUCE VARIABLE COSTS INTERNAL LAB PURSUE FDA PATHWAY PAYOR COVERAGE TARGET MULTIPLE REVENUE CHANNELS LAUNCH MULTIPLE SYNERGISTIC PRODUCTS © Cardio Diagnostics Holdings Inc., May 2023. All rights rese
Slide 22: Strong Leadership
Strong Leadership Experienced leadership, complementary backgrounds & vision to succeed. Warren Hosseinion, MD Meesha Dogan, PhD Chairman CEO, Co-Founder, & Director President, Nutex Health, Inc. (NUTX) - $407M market cap⁽¹⁾ 12+ years bridging engineering, AI, and medicine, Co-founder of Apollo Medi
Slide 23: Team Continued
Team Continued Robert Philibert, MD PhD Elisa Luqman, JD MBA CMO, Co-Founder & Director CFO 15+ years in epigenetics and clinical translation Chief Legal Officer (SEC), Nutex Health, Inc. (NUTX) Co-inventor of the Integrated Genetic-Epigenetic Engine™ Co-founder of bigVault Storage Technologies (acq
Slide 24: Team Continued
Team Continued Tim Dogan, PhD Khullani Abdullahi, JD CTO VP of Revenue & Strategy 12+ years in high performance computing systems 13+ years in commercializing complex technologies and solutions Co-inventor of the Integrated Genetic-Epigenetic Engine™ Growth architect at GreenLight Medical/Symplr, Lu
Slide 25: Achieved and Upcoming Milestones
Achieved and Upcoming Milestones Completed Q1 2023 milestones Partnerships with concierge and executive practices, Healing Sanctuary and Houston Concierge Medicine Launch of second test, PrecisionCHD™, for the detection of coronary heart disease Notice of allowance of patent in China Dr. Damon Broyl
Slide 26: Risk Factors
Risk Factors Our business is subject to numerous risks and uncertainties, including those highlighted in the section titled “Risk Factors,” that represent challenges that we face in connection with the successful implementation of our strategy and growth of our business. The occurrence of one or mor
Slide 27: Risk Factors
Risk Factors Risks Related to Government Regulation Cardio conducts business in a heavily regulated industry, and if it fails to comply with these laws and government regulations, it could incur penalties or be required to make significant changes to its operations or experience adverse publicity, w
Slide 28: For more information, please email
For more information, Revolutionizing Cardiovascular please email: Medicine With Epigenetics & AI investors@cardiodiagnosticsinc.com © Cardio Diagnostics Holdings Inc., May 2023. All rights reserved.
Slide 29: Appendix
APPENDIX Revolutionizing Cardiovascular Medicine With Epigenetics and AI
Slide 30: Cardiovascular Disease and Associated Co-Morbidities
Cardiovascular Disease and Associated Co-Morbidities In the US, nearly 18 million Americans have some type of cardiovascular disease (CVD), and CVD is responsible for both 1 in every 4 deaths and nearly $1 billion/day in medical costs + lost productivity.⁽¹⁾⁽²⁾ CORONARY HEART CONGESTIVE HEART STROKE
Slide 31: Epi+Gen CHD: Only Epigenetics-Based Test for CHD Risk Assessment
Epi+Gen CHD™: The Only Epigenetics-Based Test For Coronary Heart Disease Risk Assessment Epi+Gen CHD™ is Cardio Diagnostics’ first product that was developed using our AI-driven Integrated Genetic-Epigenetic Engine™ and was validated in collaboration with Intermountain Healthcare. Epi+Gen CHD™ is a
Slide 32: PrecisionCHD: Only Epigenetics-Based Test for CHD Detection
PrecisionCHD™: The Only Epigenetics-Based Test For Coronary Heart Disease Detection PrecisionCHD™ is Cardio Diagnostics’ second product that was developed using our AI-driven Integrated Genetic-Epigenetic Engine™ and was validated in collaboration with Intermountain Healthcare and University of Iowa
Slide 33: Actionable Clinical Intelligence: Personalizing Clinical Decision Making
Actionable Clinical Intelligence™: Assisting Clinicians in Personalizing Clinical Decision Making A one-of-a-kind platform that offers new epigenetic and genetic insights to clinicians prescribing the Epi+Gen CHD™ and PrecisionCHD™ tests. These insights are: Generated by integrating the test results
Slide 34: Epi+Gen CHD and PrecisionCHD: Next Generation Tests (Epi+Gen CHD)
Epi+Gen CHD™ and PrecisionCHD™ are the Next Generation Tests for Cardiovascular Medicine Patient 35-75 years old Have not developed signs or symptoms associated with coronary heart disease (CHD) Have not been diagnosed with CHD Need to undergo testing for primary prevention of CHD Without Epi+Gen CH
Slide 35: Epi+Gen CHD and PrecisionCHD: Next Generation Tests (PrecisionCHD)
Epi+Gen CHD™ and PrecisionCHD™ are the Next Generation Tests for Cardiovascular Medicine Patient 35-80 years old Presenting to be evaluated for CHD Need to undergo testing for the detection of CHD Without PrecisionCHD™ With PrecisionCHD™ Requires in-person clinic visit that may take days, weeks or C
Slide 36: CardioInnovate360: A BioPharma Research System
CardioInnovate360™: A BioPharma Research System That Harnessess the Power of Epigenetics, Genetics and Artificial Intelligence CardioInnovate360™ is a research-use-only (RUO) solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management o
Slide 37: Solutions Backed by Comprehensive Evidence
Cardio Diagnostics' Solutions are Backed by Comprehensive Evidence that Matter to Healthcare Stakeholders Rigorous clinical and analytic validation of biomarkers and Artificial Intelligence models Dogan et al, 2021, External Validation of Integrated Genetic-Epigenetic Biomarkers for Predicting Incid
Slide 38: Supply Chain & Laboratory Strategy
Supply Chain & Laboratory Strategy SAMPLE COLLECTION KIT LABORATORY STRATEGY CONTENTS & ASSEMBLY Common kit contents that can be sourced from Favorable agreement in place with an experienced multiple distributors laboratory Identified multiple distributors to diversify supply Refine plan to meet sam
Slide 39: Gross Margin Expansion Opportunity
Gross Margin Expansion Opportunity 1 Potential lab acquisition or set up 2 Process larger sample batches 3 Increase processing automation 4 Bulk shipping of sample collection kits and/or samples © Cardio Diagnostics Holdings Inc., May 2023. All rights reserved.
Slide 40: Product and Company Recognitions
Product and Company Recognitions Disruptive Technology Award Semifinalist ⁽¹⁾ ⁽¹⁾ Finalists to be announced around May 24, 2023 © Cardio Diagnostics Holdings Inc., May 2023. All rights reserved.
Cardio Diagnostics Holdings — Corporate Update (May 2023) on 6ix